Health
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A – Science
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the…
Abstract
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture. Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2…
-
Noosa News19 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News18 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General22 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General22 hours agoDisloyal far-left breakaways are coming for Labor